PDGFRB and neoplasm: Sorafenib simultaneously inhibits several components of the Raf-MEK-ERK signaling pathway, thus preventing tumor growth and VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-b, to inhibit neoangiogenesis [41].